Showing results (71-80 of 99) with videos related to
Sort By:
Pageof 10
Breast Cancer Research and Treatment|June 17, 2022
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysisTal Sella, Pedro Exman, Siyang Ren, et al.JCO Precision Oncology|November 22, 2023
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency SignatureFelipe Batalini, Russell W Madison, Ethan S Sokol, et al.The Oncologist|May 20, 2023
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and ControversiesStefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, et al.Breast Cancer Research and Treatment|August 21, 2021
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutationsJing Xu, Tanya E Keenan, Beth Overmoyer, et al.Breast Cancer Research and Treatment|July 24, 2021
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancerSara M Balch, Ines Vaz-Luis, Tianyu Li, et al.Journal of Surgical Oncology|July 10, 2016
Immediate breast reconstruction following mastectomy in pregnant women with breast cancerDiana L Caragacianu, Erica L Mayer, Yoon S Chun, et al.British Journal of Cancer|April 12, 2019
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutationKelly Metcalfe, Andrea Eisen, Leigha Senter, et al.Transactions of the Royal Society of Tropical Medicine and Hygiene|September 19, 2006
Accuracy of the health information system on malaria surveillance in VietnamA Erhart, N D Thang, N X Xa, et al.Future Oncology (London, England)|October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancerCiara C O'Sullivan, Karla V Ballman, Linda McCall, et al.Alimentary Pharmacology & Therapeutics|November 18, 2003
A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese populationB C-Y Wong, W M Wong, K L Cheung, et al.Pageof 10